Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tailoring neoadjuvant therapy in hormone receptor-positive, HER2-negative luminal breast cancer
2017-000676-29Phase 2Active
- Sponsor
- Borstkanker Onderzoek Groep
- Start
- Nov 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of ribociclib and letrozole in breast cancer (2 arms), sponsored by Borstkanker Onderzoek Groep. Primary endpoint: Complete cell cycle arrest in surgical specimen. Started Nov 2017; status: active.
02
Drugs
ribociclibletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2017-000676-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000676-29.